CP-640186
a potent inhibitor of mammalian Acetyl-coenzyme A carboxylases & can reduce body weight and improve insulin sensitivity in test animals; structure in first source
Networked: 2
relevant articles (0 outcomes,
0 trials/studies)
Bio-Agent Context: Research Results
Experts
| 1. | Li, Jiang:
1 article
(09/2004)
|
| 2. | Tong, Liang:
1 article
(09/2004)
|
| 3. | Tweel, Benjamin:
1 article
(09/2004)
|
| 4. | Zhang, Hailong:
1 article
(09/2004)
|
| 5. | Chapman, Justin G:
1 article
(09/2003)
|
| 6. | Dalvie, Deepak K:
1 article
(09/2003)
|
| 7. | Eisenbeis, Shane A:
1 article
(09/2003)
|
| 8. | Hargrove, Diane M:
1 article
(09/2003)
|
| 9. | Harwood, H James:
1 article
(09/2003)
|
| 10. | Magee, William P:
1 article
(09/2003)
|
Related Diseases
| 1. | Metabolic Syndrome (Dysmetabolic Syndrome X)
09/26/2003
- " In rats, CP-640186 lowered hepatic, soleus muscle, quadriceps muscle, and cardiac muscle malonyl-CoA with ED50s of 55, 6, 15, and 8 mg/kg. Consequently, CP-640186 inhibited fatty acid synthesis in rats, CD1 mice, and ob/ob mice with ED50s of 13, 11, and 4 mg/kg, and stimulated rat whole body fatty acid oxidation with an ED50 of approximately 30 mg/kg. Taken together, These observations indicate that isozyme-nonselective ACC inhibition has the potential to favorably affect risk factors associated with the metabolic syndrome."
|
| 2. | Insulin Resistance
|
| 3. | Body Weight (Weight, Body)
|
|
Related Drugs and Biologics